Therapeutic target for the treatment of cancers and related therapies and methods

Patent metadata

Field	Value
Publication number	US-9763905-B2
Application number	US-201414777485-A
Country	US
Kind code	B2
Filing date	Mar 17, 2014
Priority date	Mar 15, 2013
Publication date	Sep 19, 2017
Grant date	Sep 19, 2017

Abstract

Disclosed herein are compositions and methods for treating or preventing certain cancers in a subject. In certain embodiments such compositions and methods generally relate to the use of G-coupled protein receptor 40 (GPR40) agonists to inhibit the growth or induce apoptosis of certain cancer cells. The compositions and related methods disclosed herein may be used to treat subjects affected by cancers, such as melanoma, medullary thyroid carcinoma, malignant peripheral nerve sheath tumors and neuroblastoma, and to reduce the incidence of metastases in such affected subjects.

First claim

What is claimed is:

1. A method of treating melanoma in a subject affected by melanoma, wherein the method comprises administering a composition to the subject and thereby treating the melanoma, wherein the composition comprises an effective amount of a G-protein coupled receptor 40 (GPR40) agonist; and wherein the GPR40 agonist is not an omega-3 fatty acid, an omega-6 fatty acid, or compound C.

2. The method of claim 1 , wherein the G-protein coupled receptor 40 (GPR40) agonist comprises TAK-875 or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein the G-protein coupled receptor 40 (GPR40) agonist is selected from the group consisting of GW9508, TAK-875, AMG-837, TUG-469, compound 4p, and pharmaceutically acceptable salts thereof.

4. The method of claim 1 , wherein the method further comprises administering an effective amount of one or more chemotherapeutic agents to the subject.

5. The method of claim 1 , wherein the subject is a mammal.

6. The method of claim 1 , wherein the subject is a human.

7. The method of claim 1 , wherein the composition is administered orally, subcutaneously, topically, or intravenously to the subject.

Assignees

• Children'S Medical Center Corp
• The Children'S Medical Center Corp

Inventors

• Puder Mark
• Nehra Deepika
• Kalish Brian

Classifications

• A61K31/201

  having one or two double bonds, e.g. oleic, linoleic acids · CPC title

• A61K31/343

  condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone · CPC title

• A61K31/20

  having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids · CPC title

• A61K31/196

  the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil · CPC title

• A61K31/202 Primary

  having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557) · CPC title